1,2-O-Isopropylidene-beta-D-fructopyranoseCAS# 66900-93-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 66900-93-4 | SDF | Download SDF |
| PubChem ID | 10751385 | Appearance | Cryst. |
| Formula | C9H16O6 | M.Wt | 220.2 |
| Type of Compound | Saccharides | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (5S,6S,7R,8R)-2,2-dimethyl-1,3,10-trioxaspiro[4.5]decane-6,7,8-triol | ||
| SMILES | CC1(OCC2(O1)C(C(C(CO2)O)O)O)C | ||
| Standard InChIKey | NCPKAWHTYZABFG-JAKMQLQISA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Standard reference |
| In vitro | Synthesis of a poly-hydroxypyrolidine-based inhibitor of Mycobacterium tuberculosis GlgE.[Pubmed: 25137149]J Org Chem. 2014 Oct 17;79(20):9444-50.Long treatment times, poor drug compliance, and natural selection during treatment of Mycobacterium tuberculosis (Mtb) have given rise to extensively drug-resistant tuberculosis (XDR-TB). As a result, there is a need to identify new antituberculosis drug targets.
|
1,2-O-Isopropylidene-beta-D-fructopyranose Dilution Calculator
1,2-O-Isopropylidene-beta-D-fructopyranose Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.5413 mL | 22.7066 mL | 45.4133 mL | 90.8265 mL | 113.5332 mL |
| 5 mM | 0.9083 mL | 4.5413 mL | 9.0827 mL | 18.1653 mL | 22.7066 mL |
| 10 mM | 0.4541 mL | 2.2707 mL | 4.5413 mL | 9.0827 mL | 11.3533 mL |
| 50 mM | 0.0908 mL | 0.4541 mL | 0.9083 mL | 1.8165 mL | 2.2707 mL |
| 100 mM | 0.0454 mL | 0.2271 mL | 0.4541 mL | 0.9083 mL | 1.1353 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Talniflumate
Catalog No.:BCC7391
CAS No.:66898-62-2
- H-D-Leu-OBzl.HCl
Catalog No.:BCC2682
CAS No.:66866-69-1
- Halobetasol Propionate
Catalog No.:BCC4664
CAS No.:66852-54-8
- LDN 57444
Catalog No.:BCC2087
CAS No.:668467-91-2
- Linagliptin (BI-1356)
Catalog No.:BCC2110
CAS No.:668270-12-0
- Magnoflorine chloride
Catalog No.:BCN2405
CAS No.:6681-18-1
- Jatrorrhizine chloride
Catalog No.:BCN4956
CAS No.:6681-15-8
- Hernandezine
Catalog No.:BCN7793
CAS No.:6681-13-6
- (+/-)-Forbesione
Catalog No.:BCN6423
CAS No.:667914-50-3
- Syringaresinol-di-O-glucoside
Catalog No.:BCN2600
CAS No.:66791-77-3
- Impurity B of Calcitriol
Catalog No.:BCC1645
CAS No.:66791-71-7
- Platycodin A
Catalog No.:BCN7997
CAS No.:66779-34-8
- α-Conotoxin PIA
Catalog No.:BCC5976
CAS No.:669050-68-4
- Beta-Belladonnine
Catalog No.:BCN1893
CAS No.:6696-63-5
- Tianeptine
Catalog No.:BCC1999
CAS No.:66981-73-5
- Thiamine hydrochloride
Catalog No.:BCN2225
CAS No.:67-03-8
- EGTA
Catalog No.:BCC7491
CAS No.:67-42-5
- Furazolidone
Catalog No.:BCC8988
CAS No.:67-45-8
- 5-Hydroxymethylfurfural
Catalog No.:BCN4226
CAS No.:67-47-0
- Fluocinolone Acetonide
Catalog No.:BCC4906
CAS No.:67-73-2
- Dicyclomine HCl
Catalog No.:BCC3762
CAS No.:67-92-5
- Vitamin D3
Catalog No.:BCN2186
CAS No.:67-97-0
- Gliotoxin
Catalog No.:BCN3894
CAS No.:67-99-2
- Anthriscusin
Catalog No.:BCN3533
CAS No.:67008-16-6
Synthesis of a poly-hydroxypyrolidine-based inhibitor of Mycobacterium tuberculosis GlgE.[Pubmed:25137149]
J Org Chem. 2014 Oct 17;79(20):9444-50.
Long treatment times, poor drug compliance, and natural selection during treatment of Mycobacterium tuberculosis (Mtb) have given rise to extensively drug-resistant tuberculosis (XDR-TB). As a result, there is a need to identify new antituberculosis drug targets. Mtb GlgE is a maltosyl transferase involved in alpha-glucan biosynthesis. Mutation of GlgE in Mtb increases the concentration of maltose-1-phosphate (M1P), one substrate for GlgE, causing rapid cell death. We have designed 2,5-dideoxy-3-O-alpha-d-glucopyranosyl-2,5-imino-d-mannitol (9) to act as an inhibitor of GlgE. Compound 9 was synthesized using a convergent synthesis by coupling thioglycosyl donor 14 and 5-azido-3-O-benzyl-5-deoxy-1,2-O-Isopropylidene-beta-D-fructopyranose (23) to form disaccharide 24. A reduction and intramolecular reductive amination transformed the intermediate disaccharide 24 to the desired pyrolidine 9. Compound 9 inhibited both Mtb GlgE and a variant of Streptomyces coelicolor (Sco) GlgEI with Ki = 237 +/- 27 muM and Ki = 102 +/- 7.52 muM, respectively. The results confirm that a Sco GlgE-V279S variant can be used as a model for Mtb GlgE. In conclusion, we designed a lead transition state inhibitor of GlgE, which will be instrumental in further elucidation of the enzymatic mechanism of Mtb GlgE.
